株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

放射性医薬品の世界市場 - 産業考察、動向、見通し、市場機会の分析 2016年~2024年

Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

発行 Coherent Market Insights 商品コード 865082
出版日 ページ情報 英文 279 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
放射性医薬品の世界市場 - 産業考察、動向、見通し、市場機会の分析 2016年~2024年 Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
出版日: 2019年05月10日 ページ情報: 英文 279 Pages
概要

世界の放射性医薬品市場は、ルタセラをはじめとする放射性核種の新規承認や、放射性医薬品の用途拡大、モノクローナル抗体の放射性標識、癌やアルツハイマー病などの早期診断の必要性の高まりなどによって成長が促進される見通しです。

当レポートでは、世界の放射性医薬品市場を調査し、市場の概要、製品タイプ・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 仮定
  • 略語

第2章 市場範囲

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:製品タイプ別
    • 市場スニペット:用途別
    • 市場スニペット:エンドユーザー別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 規制シナリオ
  • 償還シナリオ
  • PEST分析
  • ファイブフォース分析
  • コラボレーション & パートナーシップ
  • 合併・買収
  • 主な開発動向
  • 疫学

第4章 世界の放射性医薬品市場:製品タイプ別

  • イントロダクション
  • 診断用核医学
  • 治療用核医学

第5章 世界の放射性医薬品市場:用途別

  • イントロダクション
  • 腫瘍
  • 循環器
  • 神経
  • 内分泌
  • その他

第6章 世界の放射性医薬品市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 専門クリニック
  • 診断センター

第7章 世界の放射性医薬品市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米
  • アフリカ
  • 中東

第8章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Progenics Pharmaceuticals, Inc.
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • Advanced Accelerator Applications, S.A.
    • Eli Lilly and Company

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Licensing, regulations, and use of radioisotopes in the U.S. is under agencies such as the U.S. Nuclear Regulatory Commission (NRC), the U.S. Environmental Protection Agency (EPA), the U.S. Food & Drug Administration (FDA), and respective state governments. The state governments are responsible for regulating radioactive substances that occur naturally or are produced by linear accelerators and/or cyclotrons, and EPA is responsible for among other things, setting air emission and drinking water standards for radionuclides. The U.S. Food and Drug Administration (FDA) regulates manufacturing and use of linear accelerators; granting marketing authorizations to radiopharmaceutical products for diagnostic as well as therapeutic use and other activities associated with radiopharmaceutical products.

Market Dynamics

Factors such as approval of products such as Lutathera, a potential blockbuster drug (Advanced Accelerator Applications, 2018) and Axumin (2016, Blue Earth Diagnostics) has propelled global radiopharmaceuticals in nuclear medicine market growth. Newer trends such as increasing therapeutic applications of radiopharmaceuticals and radiolabeling of monoclonal antibodies are expected to support growth of the market. Subsequently, as the need for early diagnosis of diseases such as cancer and accurate diagnosis of diseases such as Alzheimer's has become more necessary (certain products have come close to this such as Amyvid and Vizamyl) radiopharmaceuticals are expected to find an even strong foothold in medical care.

Key features of the study:

  • This report provides in-depth analysis of global radiopharmaceuticals in nuclear medicine market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation:

  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • Tc-99m
    • In-111
    • Tl-201
    • Ga-67
    • I-123/I-125/I-131
    • Other SPECT Isotopes
    • PET Radiopharmaceuticals
    • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
    • Ru-82
    • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Ra-223
    • I-131
    • Re-186/Sm-153/Sr-90
    • Lu-177
    • Ir-192
    • Pd-103
    • Cs-131
    • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
  • North America
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • U.S.
    • Canada
  • Europe
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
  • Progenics Pharmaceuticals, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • NorthStar Medical Radioisotopes LLC
  • Curium Pharma
  • Life Molecular Imaging
  • Lantheus Holdings, Inc.
  • Cardinal Health, Inc.
  • General Electric Company
  • Bracco S.p.A.
  • Bayer AG
  • Advanced Accelerator Applications, S.A.
  • Eli Lilly and Company

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Application
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Analysis
  • Collaborations & Partnerships
  • Mergers & Acquisitions
  • Key Developments
  • Epidemiology

4. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • Tc-99m
    • In-111
    • Tl-201
    • Ga-67
    • I-123/I-125/I-131
    • Other SPECT Isotopes
    • PET Radiopharmaceuticals
    • F-18
    • F-18 Florbetapir/Flutemetamol/ Florbetaben
    • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
    • Fluorine-18 Fluciclovine
    • Other F-18 Isotopes
    • Ru-82
    • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Ra-223
    • I-131
    • Re-186/Sm-153/Sr-90
    • Lu-177
    • Ir-192
    • Pd-103
    • Cs-131
    • Others

5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Cardiology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Endocrinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Global Radiopharmaceuticals in Nuclear Medicine Market, By Regions, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Progenics Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • NorthStar Medical Radioisotopes LLC
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Curium Pharma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Life Molecular Imaging
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Lantheus Holdings, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Cardinal Health, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • General Electric Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bracco S.p.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Advanced Accelerator Applications, S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top